Tu2033 – Quantitation of Methylation Load of Tumor Suppressor Gene Promoter Methylation in Pancreatic Cancer

Singh, Nidhi; Gupta, Surabhi; Rashid, Safoora; Dash, Nihar Ranjan; Saraya, Anoop

doi:10.1016/s0016-5085(19)39911-1

Cited by 5 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then, 29 articles were excluded: 18 did not have relevant outcomes reported, and 11 were without sufficient data. Finally, nine articles were eligible to be included in the meta‐analysis 20,28‐35 …”

Section: Resultsmentioning

confidence: 99%

“…As previous studies researched on novel tumour biomarkers, it was found that DNA methylation may play a significant role in cancer. Variation has been observed in methylated NPTX2 expression levels between cancer patients and benign disease controls 20,28‐35 . However, limited work has been done to perform meta‐analyses on methylated NPTX2 as a diagnostic biomarker for PC.…”

Section: Discussionmentioning

confidence: 99%

“…During the analysis of studies, the low sensitivity was that of Hiroyuki and MD, of which both collected pancreatic juice by secretin stimulation 20,33 . The use of pancreatic secretions may dilute the pancreatic juice and decreased sensitivity.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic value of neuronal pentraxin II methylation in patients with pancreatic cancer: Meta‐analysis

Huang

Lifeng

et al. 2021

Int J Clin Pract

View full text Add to dashboard Cite

Background Pancreatic cancer (PC) is a devasting disease of which mortality almost parallels its incidence. PC tissue may express aberrantly methylated neuronal pentraxin II (NPTX2), but it is unclear what the consequences of this are. Methods We systematically searched PubMed, Web of Science, the Chinese National Knowledge Infrastructure (CNKI), from inception to July 15, 2020, to identify if the detection of methylated NPTX2 have sufficient sensitivity and specificity to identify PC from other benign pancreatic diseases. Results Majority of the studies obtained samples from pancreatic juice by endoscopy or surgery and composed of population with chronic pancreatitis, benign cystic lesion, intraductal papillary mucinous neoplasm, and healthy controls. Our results demonstrated that the diagnostic value of methylated NPTX2 is of widely various sensitivity and specificity and it shown higher specificity in differentiate PC from benign diseases. The lab method of quantitative real‐time methylation‐specific PCR (QMSP) has higher specificity than real‐time methylation‐specific PCR (MSP) in detecting the indicator. Conclusions NPTX2 methylation could serve as a promising molecular biomarker for pancreatic cancer diagnosis, for its high diagnostic value in differentiating pancreatic cancer from benign pancreatic disease with the lab method. The variable sensitivity of methylated NPTX2 was multifactorial, and it must be promoted before applied as screening test in clinical practice. Furthermore, experiments on methylated NPTX2 were needed to expanded for lower the heterogeneity.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic value of neuronal pentraxin II methylation in patients with pancreatic cancer: Meta‐analysis

Huang

Lifeng

et al. 2021

Int J Clin Pract

View full text Add to dashboard Cite

show abstract

“…Of note, a recent analysis reported the first methylation landscape on tumor suppressor genes in PDAC [ 68 ]. In this study higher methylation indices for SPARC were able to distinguish PDAC from CP, confirming previous observations [ 69 ].…”

Section: Discussionmentioning

confidence: 99%

Omics Analysis of Educated Platelets in Cancer and Benign Disease of the Pancreas

Mantini

Meijer

Glogovitis

et al. 2020

Cancers

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is traditionally associated with thrombocytosis/hypercoagulation and novel insights on platelet-PDAC “dangerous liaisons” are warranted. Here we performed an integrative omics study investigating the biological processes of mRNAs and expressed miRNAs, as well as proteins in PDAC blood platelets, using benign disease as a reference for inflammatory noise. Gene ontology mining revealed enrichment of RNA splicing, mRNA processing and translation initiation in miRNAs and proteins but depletion in RNA transcripts. Remarkably, correlation analyses revealed a negative regulation on SPARC transcription by isomiRs involved in cancer signaling, suggesting a specific ”education” in PDAC platelets. Platelets of benign patients were enriched for non-templated additions of G nucleotides (#ntaG) miRNAs, while PDAC presented length variation on 3′ (lv3p) as the most frequent modification on miRNAs. Additionally, we provided an actionable repertoire of PDAC and benign platelet-ome to be exploited for future studies. In conclusion, our data show that platelets change their biological repertoire in patients with PDAC, through dysregulation of miRNAs and splicing factors, supporting the presence of de novo protein machinery that can “educate” the platelet. These novel findings could be further exploited for innovative liquid biopsies platforms as well as possible therapeutic targets.

show abstract

“…More information on the cfDNA methylation state of three of these genes was provided by a recent preliminary work from Singh and colleagues [61]. The authors assessed by QMSP ( Table 1) the absolute copy number of methylated or unmethylated NPTX2, PENK, SPARC, and UCHL1 cfDNA in individuals suffering from PDAC or CP, compared to healthy subjects.…”

Section: Cfdna Hypermethylated Targetsmentioning

confidence: 99%

Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers’ Discovery

Brancaccio

Natale

Falco

et al. 2019

Genes

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancer types world-wide. Its high mortality is related to the difficulty in the diagnosis, which often occurs when the disease is already advanced. As of today, no early diagnostic tests are available, while only a limited number of prognostic tests have reached clinical practice. The main reason is the lack of reliable biomarkers that are able to capture the early development or the progression of the disease. Hence, the discovery of biomarkers for early diagnosis or prognosis of PDAC remains, de facto, an unmet need. An increasing number of studies has shown that cell-free DNA (cfDNA) methylation analysis represents a promising non-invasive approach for the discovery of biomarkers with diagnostic or prognostic potential. In particular, cfDNA methylation could be utilized for the identification of disease-specific signatures in pre-neoplastic lesions or chronic pancreatitis (CP), representing a sensitive and non-invasive method of early diagnosis of PDAC. In this review, we will discuss the advantages and pitfalls of cfDNA methylation studies. Further, we will present the current advances in the discovery of pancreatic cancer biomarkers with early diagnostic or prognostic potential, focusing on pancreas-specific (e.g., CUX2 or REG1A) or abnormal (e.g., ADAMTS1 or BNC1) cfDNA methylation signatures in high risk pre-neoplastic conditions and PDAC.

show abstract

Tu2033 – Quantitation of Methylation Load of Tumor Suppressor Gene Promoter Methylation in Pancreatic Cancer

Cited by 5 publications

References 0 publications

Diagnostic value of neuronal pentraxin II methylation in patients with pancreatic cancer: Meta‐analysis

Diagnostic value of neuronal pentraxin II methylation in patients with pancreatic cancer: Meta‐analysis

Omics Analysis of Educated Platelets in Cancer and Benign Disease of the Pancreas

Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers’ Discovery

Contact Info

Product

Resources

About